Answers are grounded in this paper and cite their sources.
Shows enhanced islet function in animals using Adoshell, indicating potential for diabetes treatment.
Introduction and Objective: AdoShell® is an implantable and fully retrievable matrix for islet transplantation aiming to cure diabetes by cell therapy without immunosuppression. It features a hydrogel allowing insulin diffusion while preventing immune cells and antibody exposure. It is reinforced with a surgical mesh and silicon sheets. It has demonstrated immunoprotection and islet functionality in vitro and in vivo. AdoShell® was scaled up for clinical application to enable the loading of a therapeutically relevant quantity of islets. A surgical procedure for implantation by laparoscopy was developed. Methods: AdoShell® Islets was manufactured with human islets. Functionality was evaluated by glucose stimulated insulin secretion assay and islet distribution by imaging. Transplantation was performed by laparotomy in rodents and laparoscopy in pigs. Results: AdoShell® Islets showed robust in vivo insulin secretion in immunocompetent rats transplanted with allogenic islets (N=4, n=25 rats, 40 days), and in immunodeficient mice with human islets (N=4, n=20 mice, 12 weeks) or sc-islets (N=2, n=15 mice, 19-25 weeks). AdoShell® was optimized with a multi-compartment design embarking up to 150 kIEQ. Its shape and size allow transplantation of multiple devices for a dose up to 750 kIEQ. Furthermore, the implant was designed for laparoscopic implantation and stapling at the implantation site, the reinforcement frame ensuring high resistance to folding. AdoShell® islets can be manufactured at the islet isolation unit from ready-to-use GMP-compliant reagents. Islets are homogeneously distributed intra and inter compartments (CV=9%) and preserve viability and function throughout the manufacturing process A surgical procedure with a protective sleeve was developed to deliver the implant while maintaining its integrity. Conclusion: In addition to the established immunoprotection and survival of human islets in AdoShell, the development towards First in Human was completed by the manufacturing process and surgical procedure. Disclosure A. Martin: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. R. Besnard: Employee; Current; ADOCIA. J. Brun: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. G. Lefebvre: None. C. Gautier: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. G. Baud: None. C. Mégret: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. A. Gaffuri: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. O. Jouannot: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. N. Laurent: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. M. Gaudier: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. R. Eloy: Employee; Ended; ADOCIA. Stock/Shareholder; Current; ADOCIA. F. Pattou: Advisory Panel; Current; Lilly. Consultant; Current; Novo Nordisk. Advisory Panel; Current; Boehringer Ingelheim International GmbH. Consultant; Ended; Medtronic. Consultant; Current; Ethicon, Inc., ADOCIA. O. Soula: Board Member; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. Employee; Current; ADOCIA.
No takes yet. Share an insight, caveat, or question.
Martin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: